In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions- a metabolic approach

Autores
Silva, Luciana Damacena; Lima, Nayana Ferreira; Arrua, Eva Carolina; Salomon, Claudio Javier; Vinaud, Marina Clare
Año de publicación
2018
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Neurocysticercosis is the most common parasitic infection of the nervous system and currently represents a serious public health issue in many regions of Latin America, Asia, and Africa. To date, praziquantel is one of the chosen drugs for the treatment of neurocysticercosis. Its mechanism of action is based on the inhibition of different biochemical pathways within the parasite which contribute to its death. Thus, the aim of this work was to analyze, for the first time, whether the nanoformulations of praziquantel would modify the energetic pathway of Taenia crassiceps cysticerci, after an intracranial inoculation in BALB/c mice. Praziquantel nanosuspensions were formulated with polyvinyl alcohol, poloxamer 188, and poloxamer 407, as stabilizers. These formulations exhibited particle size in a range of 74–285 nm and zeta potential values in a range of − 8.1/− 13.2 depending on the type of stabilizer. Physical stability study at both 4 ± 2 and 25 ± 2 °C indicated that praziquantel (PZQ) nanoparticles were stable in terms of solubility and particle size after 120-day storage. In vivo studies demonstrated that those nanosystems were able to produce significant modifications on the concentrations of oxaloacetate, citrate, pyruvate, alpha-ketoglutarate, malate, succinate, lactate, beta-hydroxybutyrate, fumarate, and propionate involved in the metabolism of Taenia crassiceps cysticerci. Therefore, these nanoformulations may be considered as a promising tool to deliver praziquantel to the brain for the effective management of neurocysticercosis.
Fil: Silva, Luciana Damacena. Universidade Federal de Goiás; Brasil
Fil: Lima, Nayana Ferreira. Universidade Federal de Goiás; Brasil
Fil: Arrua, Eva Carolina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
Fil: Salomon, Claudio Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
Fil: Vinaud, Marina Clare. Universidade Federal de Goiás; Brasil
Materia
IN VIVO
NANOTECHNOLOGY
NEUROCYSTICERCOSIS
PRAZIQUANTEL
TAENIA CRASSICEPS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/89703
Acceder
id CONICETDig_94f855b095e7f3dc3c3c09966bda2e8a
oai_identifier_str oai:ri.conicet.gov.ar:11336/89703
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions- a metabolic approachSilva, Luciana DamacenaLima, Nayana FerreiraArrua, Eva CarolinaSalomon, Claudio JavierVinaud, Marina ClareIN VIVONANOTECHNOLOGYNEUROCYSTICERCOSISPRAZIQUANTELTAENIA CRASSICEPShttps://purl.org/becyt/ford/2.10https://purl.org/becyt/ford/2Neurocysticercosis is the most common parasitic infection of the nervous system and currently represents a serious public health issue in many regions of Latin America, Asia, and Africa. To date, praziquantel is one of the chosen drugs for the treatment of neurocysticercosis. Its mechanism of action is based on the inhibition of different biochemical pathways within the parasite which contribute to its death. Thus, the aim of this work was to analyze, for the first time, whether the nanoformulations of praziquantel would modify the energetic pathway of Taenia crassiceps cysticerci, after an intracranial inoculation in BALB/c mice. Praziquantel nanosuspensions were formulated with polyvinyl alcohol, poloxamer 188, and poloxamer 407, as stabilizers. These formulations exhibited particle size in a range of 74–285 nm and zeta potential values in a range of − 8.1/− 13.2 depending on the type of stabilizer. Physical stability study at both 4 ± 2 and 25 ± 2 °C indicated that praziquantel (PZQ) nanoparticles were stable in terms of solubility and particle size after 120-day storage. In vivo studies demonstrated that those nanosystems were able to produce significant modifications on the concentrations of oxaloacetate, citrate, pyruvate, alpha-ketoglutarate, malate, succinate, lactate, beta-hydroxybutyrate, fumarate, and propionate involved in the metabolism of Taenia crassiceps cysticerci. Therefore, these nanoformulations may be considered as a promising tool to deliver praziquantel to the brain for the effective management of neurocysticercosis.Fil: Silva, Luciana Damacena. Universidade Federal de Goiás; BrasilFil: Lima, Nayana Ferreira. Universidade Federal de Goiás; BrasilFil: Arrua, Eva Carolina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaFil: Salomon, Claudio Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; ArgentinaFil: Vinaud, Marina Clare. Universidade Federal de Goiás; BrasilSpringer Verlag Berlín2018-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/89703Silva, Luciana Damacena; Lima, Nayana Ferreira; Arrua, Eva Carolina; Salomon, Claudio Javier; Vinaud, Marina Clare; In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions- a metabolic approach; Springer Verlag Berlín; Drug Delivery and Translational Research; 8; 5; 10-2018; 1265-12732190-393X2190-3948CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007%2Fs13346-018-0576-7info:eu-repo/semantics/altIdentifier/doi/10.1007/s13346-018-0576-7info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:49:56Zoai:ri.conicet.gov.ar:11336/89703instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:49:56.998CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions- a metabolic approach
title In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions- a metabolic approach
spellingShingle In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions- a metabolic approach
Silva, Luciana Damacena
IN VIVO
NANOTECHNOLOGY
NEUROCYSTICERCOSIS
PRAZIQUANTEL
TAENIA CRASSICEPS
title_short In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions- a metabolic approach
title_full In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions- a metabolic approach
title_fullStr In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions- a metabolic approach
title_full_unstemmed In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions- a metabolic approach
title_sort In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions- a metabolic approach
dc.creator.none.fl_str_mv Silva, Luciana Damacena
Lima, Nayana Ferreira
Arrua, Eva Carolina
Salomon, Claudio Javier
Vinaud, Marina Clare
author Silva, Luciana Damacena
author_facet Silva, Luciana Damacena
Lima, Nayana Ferreira
Arrua, Eva Carolina
Salomon, Claudio Javier
Vinaud, Marina Clare
author_role author
author2 Lima, Nayana Ferreira
Arrua, Eva Carolina
Salomon, Claudio Javier
Vinaud, Marina Clare
author2_role author
author
author
author
dc.subject.none.fl_str_mv IN VIVO
NANOTECHNOLOGY
NEUROCYSTICERCOSIS
PRAZIQUANTEL
TAENIA CRASSICEPS
topic IN VIVO
NANOTECHNOLOGY
NEUROCYSTICERCOSIS
PRAZIQUANTEL
TAENIA CRASSICEPS
purl_subject.fl_str_mv https://purl.org/becyt/ford/2.10
https://purl.org/becyt/ford/2
dc.description.none.fl_txt_mv Neurocysticercosis is the most common parasitic infection of the nervous system and currently represents a serious public health issue in many regions of Latin America, Asia, and Africa. To date, praziquantel is one of the chosen drugs for the treatment of neurocysticercosis. Its mechanism of action is based on the inhibition of different biochemical pathways within the parasite which contribute to its death. Thus, the aim of this work was to analyze, for the first time, whether the nanoformulations of praziquantel would modify the energetic pathway of Taenia crassiceps cysticerci, after an intracranial inoculation in BALB/c mice. Praziquantel nanosuspensions were formulated with polyvinyl alcohol, poloxamer 188, and poloxamer 407, as stabilizers. These formulations exhibited particle size in a range of 74–285 nm and zeta potential values in a range of − 8.1/− 13.2 depending on the type of stabilizer. Physical stability study at both 4 ± 2 and 25 ± 2 °C indicated that praziquantel (PZQ) nanoparticles were stable in terms of solubility and particle size after 120-day storage. In vivo studies demonstrated that those nanosystems were able to produce significant modifications on the concentrations of oxaloacetate, citrate, pyruvate, alpha-ketoglutarate, malate, succinate, lactate, beta-hydroxybutyrate, fumarate, and propionate involved in the metabolism of Taenia crassiceps cysticerci. Therefore, these nanoformulations may be considered as a promising tool to deliver praziquantel to the brain for the effective management of neurocysticercosis.
Fil: Silva, Luciana Damacena. Universidade Federal de Goiás; Brasil
Fil: Lima, Nayana Ferreira. Universidade Federal de Goiás; Brasil
Fil: Arrua, Eva Carolina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
Fil: Salomon, Claudio Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
Fil: Vinaud, Marina Clare. Universidade Federal de Goiás; Brasil
description Neurocysticercosis is the most common parasitic infection of the nervous system and currently represents a serious public health issue in many regions of Latin America, Asia, and Africa. To date, praziquantel is one of the chosen drugs for the treatment of neurocysticercosis. Its mechanism of action is based on the inhibition of different biochemical pathways within the parasite which contribute to its death. Thus, the aim of this work was to analyze, for the first time, whether the nanoformulations of praziquantel would modify the energetic pathway of Taenia crassiceps cysticerci, after an intracranial inoculation in BALB/c mice. Praziquantel nanosuspensions were formulated with polyvinyl alcohol, poloxamer 188, and poloxamer 407, as stabilizers. These formulations exhibited particle size in a range of 74–285 nm and zeta potential values in a range of − 8.1/− 13.2 depending on the type of stabilizer. Physical stability study at both 4 ± 2 and 25 ± 2 °C indicated that praziquantel (PZQ) nanoparticles were stable in terms of solubility and particle size after 120-day storage. In vivo studies demonstrated that those nanosystems were able to produce significant modifications on the concentrations of oxaloacetate, citrate, pyruvate, alpha-ketoglutarate, malate, succinate, lactate, beta-hydroxybutyrate, fumarate, and propionate involved in the metabolism of Taenia crassiceps cysticerci. Therefore, these nanoformulations may be considered as a promising tool to deliver praziquantel to the brain for the effective management of neurocysticercosis.
publishDate 2018
dc.date.none.fl_str_mv 2018-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/89703
Silva, Luciana Damacena; Lima, Nayana Ferreira; Arrua, Eva Carolina; Salomon, Claudio Javier; Vinaud, Marina Clare; In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions- a metabolic approach; Springer Verlag Berlín; Drug Delivery and Translational Research; 8; 5; 10-2018; 1265-1273
2190-393X
2190-3948
CONICET Digital
CONICET
url http://hdl.handle.net/11336/89703
identifier_str_mv Silva, Luciana Damacena; Lima, Nayana Ferreira; Arrua, Eva Carolina; Salomon, Claudio Javier; Vinaud, Marina Clare; In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions- a metabolic approach; Springer Verlag Berlín; Drug Delivery and Translational Research; 8; 5; 10-2018; 1265-1273
2190-393X
2190-3948
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007%2Fs13346-018-0576-7
info:eu-repo/semantics/altIdentifier/doi/10.1007/s13346-018-0576-7
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer Verlag Berlín
publisher.none.fl_str_mv Springer Verlag Berlín
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269003412668416
score 13.13397

Publicaciones similares